Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 11
2003 13
2004 3
2005 4
2006 13
2007 16
2008 9
2009 8
2010 10
2011 7
2012 5
2013 3
2014 2
2015 4
2016 5
2017 7
2018 10
2019 8
2020 10
2021 11
2022 16
2023 12
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

175 results

Results by year

Filters applied: . Clear all
Page 1
A Risk Stratification System in Myeloma Patients with Autologous Stem Cell Transplantation.
Guo W, Strouse C, Mery D, Siegel ER, Munshi MN, Ashby TC, Cheng Y, Sun F, Wanchai V, Zhang Z, Bailey C, Alapat DV, Peng H, Al Hadidi S, Thanendrarajan S, Schinke C, Zangari M, van Rhee F, Tricot G, Shaughnessy JD Jr, Zhan F. Guo W, et al. Among authors: zangari m. Cancers (Basel). 2024 Mar 11;16(6):1116. doi: 10.3390/cancers16061116. Cancers (Basel). 2024. PMID: 38539451 Free PMC article.
Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study.
Mohan M, Monge J, Shah N, Luan D, Forsberg M, Bhatlapenumarthi V, Balev M, Patwari A, Cheruvalath H, Bhutani D, Thanendrarajan S, Dhakal B, Zangari M, Al-Hadidi S, Cooper D, Lentzsch S, van Rhee F, D'Souza A, Szabo A, Schinke C, Chakraborty R. Mohan M, et al. Among authors: zangari m. Blood Cancer J. 2024 Mar 5;14(1):35. doi: 10.1038/s41408-024-01003-z. Blood Cancer J. 2024. PMID: 38443345 Free PMC article.
Autologous stem cell boost improves persistent immune effector cell associated hematotoxicity following BCMA directed chimeric antigen receptor T (CAR T) cell therapy in multiple myeloma.
Mohan M, Szabo A, Patwari A, Esselmann J, Patel T, Bachu R, Rein LE, Janardan A, Bhatlapenumarthi V, Annyapu E, Skoog C, Goff A, Hadidi SA, Radhakrishnan SV, Thanendrarajan S, Zangari M, Shah N, van Rhee F, Dhakal B, Hamadani M, D'Souza A, Schinke C. Mohan M, et al. Among authors: zangari m. Bone Marrow Transplant. 2024 Feb 15. doi: 10.1038/s41409-024-02233-2. Online ahead of print. Bone Marrow Transplant. 2024. PMID: 38361116
Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systems.
Guo W, Zhan Y, Mery D, Siegel ER, Sun F, Cheng Y, Ashby TC, Zhang Z, Bailey C, Alapat DV, Peng H, Hadidi SA, Thanendrarajan S, Schinke C, Zangari M, van Rhee F, Tricot G, Shaughnessy JD, Zhan F. Guo W, et al. Among authors: zangari m. Blood Cancer J. 2024 Feb 14;14(1):30. doi: 10.1038/s41408-024-00998-9. Blood Cancer J. 2024. PMID: 38355688 Free PMC article. No abstract available.
Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth.
Sun F, Cheng Y, Wanchai V, Guo W, Mery D, Xu H, Gai D, Siegel E, Bailey C, Ashby C, Al Hadidi S, Schinke C, Thanendrarajan S, Ma Y, Yi Q, Orlowski RZ, Zangari M, van Rhee F, Janz S, Bishop G, Tricot G, Shaughnessy JD Jr, Zhan F. Sun F, et al. Among authors: zangari m. Nat Commun. 2024 Jan 19;15(1):615. doi: 10.1038/s41467-024-44873-4. Nat Commun. 2024. PMID: 38242888 Free PMC article.
Three years of maintenance with VRD in multiple myeloma: results of total therapy IIIB with a 15-year follow-up.
Al Hadidi S, Ababneh OE, Schinke CD, Thanendrarajan S, Bailey C, Smith R, Panozzo S, Alapat D, Cottler-Fox M, Tricot G, Shaughnessy JD Jr, Zhan F, Sawyer J, Barlogie B, Zangari M, van Rhee F. Al Hadidi S, et al. Among authors: zangari m. Blood Adv. 2024 Feb 13;8(3):703-707. doi: 10.1182/bloodadvances.2023011601. Blood Adv. 2024. PMID: 38052037 Free PMC article.
High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma.
Cheng Y, Sun F, Alapat DV, Wanchai V, Mery D, Guo W, Cao H, Zhu Y, Ashby C, Bauer MA, Nookaew I, Siegel ER, Ying J, Chen JR, Gai D, Peng B, Xu H, Bailey C, Al Hadidi S, Schinke C, Thanendrarajan S, Zangari M, Chesi M, Bergsagel PL, van Rhee F, Janz S, Tricot G, Shaughnessy JD Jr, Zhan F. Cheng Y, et al. Among authors: zangari m. Cell Rep Med. 2023 Oct 17;4(10):101214. doi: 10.1016/j.xcrm.2023.101214. Epub 2023 Oct 3. Cell Rep Med. 2023. PMID: 37794587 Free PMC article.
175 results